Health insurance idea could help millions of Americans spend less
Millions of Americans with chronic conditions could save money on the drugs and medical services they need the most, if […]
» Read moreHome »
Researchers are urging universities across the United States to find a new way to identify the next generation of scientists. […] It’s no secret that drug prices are increasing, but to what extent are rising costs explained by the advent of […] LSTM’s Professor Joseph Valadez is senior author on a new study published today in the Proceedings of the National Academy […] Australians pride themselves on having a classless society, where wealth is determined not by how rich your parents are but […] In November 1998, the world was introduced to human embryonic stem cells, the blank slate cells that arise at the […] A new study by researchers from the University of California, Riverside, and the Rotterdam School of Management finds that fear […] A substantial proportion of pharmaceutical industry payments to authors of oncology clinical trials published in major scientific journals are not […] In countries which already permit embryo research, there are no “compelling moral arguments” why the time limit for experimentation should […] Most research on learning disabilities focuses on remediating specific academic skills like reading and math. But struggles at school and […]
The GRE fails to identify students that will graduate and hurts diversity
Rising drug prices linked to older products — not just newer, better medications
Hybrid prevalence estimation: Method to improve intervention coverage estimations
Family matters for future wealth
Twenty years on, measuring the impact of human stem cells
Disruption makes startup investors balance caution against fear of missing out
Financial disclosure lacking in publication of clinical trials, study finds
Double time limit for embryo research, say ethics experts
Learning disabilities: Kids and families struggle beyond the academics: More than half report quality-of-life problems in the ‘at risk’ or ‘clinically significant’ range
